Concourse Financial Group Securities, Inc. Acurx Pharmaceuticals, Inc. Transaction History

Concourse Financial Group Securities, Inc.

$1.64 Billion
Q3 2024

Number of Shares

Previous 0 NaN%

Holding current value

Previous $0 NaN%

% of portfolio

0.0%

Previous 0.0%

15 transactions

Quarter	Operation	Price Per share
Q3 2024 Oct 10, 2024	BUY	$1.83 - $2.62 $0 - $0
Q2 2024 Jul 23, 2024	BUY	$1.64 - $2.79 $0 - $0
Q1 2024 Apr 30, 2024	BUY	$1.94 - $4.81 $0 - $0
Q4 2023 Feb 07, 2024	BUY	$1.28 - $5.76 $0 - $0
Q3 2023 Oct 30, 2023	BUY	$1.41 - $2.55 $0 - $0
Q3 2023 Oct 25, 2023	BUY	$1.41 - $2.55 $0 - $0
Q2 2023 Aug 10, 2023	BUY	$2.47 - $3.53 $0 - $0
Q1 2023 May 15, 2023	BUY	$3.06 - $4.5 $0 - $0
Q4 2022 Jan 30, 2023	BUY	$2.75 - $4.1 $0 - $0
Q3 2022 Nov 15, 2022	BUY	$3.0 - $4.78 $0 - $0
Q2 2022 Aug 09, 2022	BUY	$2.42 - $4.0 $0 - $0
Q1 2022 May 09, 2022	BUY	$3.11 - $4.74 $0 - $0
Q4 2021 Feb 07, 2022	BUY	$4.02 - $5.64 $0 - $0
Q3 2021 Nov 09, 2021	BUY	$3.77 - $6.18 $0 - $0
Q2 2021 Aug 13, 2021	BUY	$6.24 - $7.89 $0 - $0

Others Institutions Holding ACXP

# of Institutions

Shares Held

1.25M

Call Options Held

9.3K

Put Options Held

9.7K

View Full List

About Acurx Pharmaceuticals, Inc.

Ticker ACXP
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 11,556,600
Market Cap $15.6M
Description
Acurx Pharmaceuticals, Inc., a clinical stage biopharmaceutical company, develops antibiotics to treat bacterial infections. Its lead antibiotic candidate is ibezapolstat, a novel mechanism of action that targets the polymerase IIIC enzyme that has completed Phase II clinical trial to treat patients with clostridium difficile infections. The com...

More about ACXP

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Concourse Financial Group Securities, Inc., based on Form 13F filings with the SEC.

News

Stay updated on Concourse Financial Group Securities, Inc. with notifications on news.

Account